// App-Quantinova.ai

: Cost effectiveness of umeclidinium bromide 62.5μg plus ICS/LABA versus ICS/LABA in COPD

Researchers

Presenter

  • Maurice Driessen

Principal Investigators

  • Nancy Risebrough

  • Andrew Briggs

  • Afisi Ismaila

  • Dhvani Shah

  • Ian Naya

  • Timothy M Baker

Medical Centers

  • Value Evidence and Outcomes, GSK, London, United Kingdom.

  • ICON plc., Toronto, ON, Canada

  • ICON plc, NY, United States of America

  • US Value Evidence and Outcomes, GSK, Research Triangle Park, NC, United States,

  • Respiratory Medical Franchise, GSK, London, United Kingdom.

Locations

  • United Kingdom

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • N/A

Drug/Treatment

  • Umeclidinium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved